Press Center
Topics
- February 1, 2012
3rd Quarter of FY2011 financial results conference call from 4:30pm - Presenters: Director, Chief Medical & Scientific Officer, Tadataka Yamada, M.D.
Senior Vice President, Finance & Accounting Department, Hiroshi Takahara
Press Releases
- January 31, 2012
Takeda’s Annual Report 2011 and CSR Data Book 2011 Receive Special Prize in Sustainability Reporting Award - January 27, 2012
Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan - January 24, 2012
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications - January 18, 2012
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth - January 18, 2012
New Drug Application Approval for AZILVA® in Japan, a Treatment of Hypertension
Press Releases' Search
Corporate Information
| About Takeda | Investor Infomation |
| Overview Corporate Philosophy (Takeda-ism) Fundamental Policy Management Plan Core Products Reports & Publications |
Financial Highlights Quarterly Results IR Calendar |
| Corporate Responsibility | Research & Development |
| CSR in Takeda |
Core Therapeutic Areas Product Pipeline Drug Discovery |
Stock
Performance
02/03 15:00 (TSE 1st)
- Value
- 3,320 JPY
- Net change
- -15 JPY
- JIJI PRESS,LTD